Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.

Vaccine · 2010 · PMC3404461 · PMID 20937436

Europe PMC DOI

hedged sentence

0.3200

closest p · 6.4× alpha

0.3200

boldest claim

The sentences

did not reach statistical significanceP = 0.32not close (p > 0.1)

When analyzed by two-way repeat measures ANOVA, this trend did not reach statistical significance ( P = 0.32) without pooling of replicate groups (described above for A–P and A–M), though there was a significant increase in avidity over time after final vaccination across all groups ( P < 0.0001).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.